Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RHAPSIDO safely and effectively. See full prescribing information for RHAPSIDO. RHAPSIDO® (remibrutinib) tablets, for oral use Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
RHAPSIDO® is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Limitations of Use: RHAPSIDO is not indicated for other forms of urticaria.
- generic_name
- remibrutinib
- product_names
- remibrutinib
- ndc
- 0078-1483, 0078-1483-20, 0078-1483-92, 0078-1483-93
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en